Application of galactosamine alpha-2, 6-sialyltransferase in diagnosis and treatment of diffuse large B-cell lymphoma

Through the synergistic effect of ST6GALNAC4 and the synergistic effect of 3Fax-Peracetyl Neuc5Ac combined with FX1, the treatment difficulties caused by abnormal expression of ST6GALNAC4 in DLBCL were solved, effective diagnosis and prognosis evaluation of DLBCL was achieved, and the foundation was laid for the development of efficient therapeutic drugs. It significantly inhibited the proliferation and vitality of DLBCL cells.

CN118910260APending Publication Date: 2024-11-08SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY (SHANDONG PROVINCIAL HOSPITAL)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411093709.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-09
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

In the treatment of diffuse large B-cell lymphoma, the prior art is difficult to effectively identify and cope with the abnormal expression of ST6GALNAC4 and its role in tumor progression, metastasis and immune escape, resulting in recurrence or worsening of the disease in some patients.

Method used

Through studies, ST6GALNAC4-mediated sialylation is an important epigenetic modification in DLBCL. Using sialicyltransferase inhibitor 3Fax-Peracetyl Neuc5Ac combined with BCL-6 inhibitor FX1, synergistically acts to inhibit tumor cell growth, providing detection and treatment The protocol, including reagents and drug systems to detect ST6GALNAC4 expression levels, is used for screening, diagnosis, monitoring and prognosis evaluation, and to prepare substances that inhibit ST6GALNAC4 encoding genes and their expression to prepare anti-tumor drugs.

Benefits of technology

The expression of ST6GALNAC4 and its clinical significance were verified, providing a more favorable means for the diagnosis and prognostic evaluation of DLBCL, and laying the foundation for the development of efficient therapeutic drugs, significantly reducing the proliferation and vitality of DLBCL cells, and providing a new therapeutic vision. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910260A_ABST
    Figure CN118910260A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of tumor diagnosis and treatment, and particularly relates to application of galactosamine alpha-2, 6-sialyltransferase in diagnosis and treatment of diffuse large B-cell lymphoma. Specifically, research finds that ST6GALNAC4-mediated sialylation is important epigenetic modification in DLBCL, a sialyltransferase inhibitor 3Fax-Peracetyl Neuc5Ac and a BCL-6 inhibitor FX1 have a synergistic effect in diffuse large B-cell lymphoma, tumor cell growth can be effectively inhibited, and the application of the sialyltransferase inhibitor 3Fax-Peracetyl Neuc5Ac to the diffuse large B-cell lymphoma is promoted. A more favorable means is provided for diagnosis and prognosis evaluation of the diffuse large B-cell lymphoma, and meanwhile, an experimental foundation is laid and a new view is provided for developing high-efficiency related medicines for treating the diffuse large B-cell lymphoma, so that the method has a good practical application value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of tumor diagnosis and treatment, and specifically relates to the application of aminogalactose α-2,6-sialyltransferase in the diagnosis and treatment of diffuse large B-cell lymphoma. Background Art

[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.

[0003] Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL), characterized by rapid disease progression and variable clinical manifestations. Based on the expression characteristics of the gene spectrum, DLBCL can be divided into germinal center B-cell (GCB) and non-germinal center B-cell (non-GCB), and patients of different subtypes have different responses to treatment and prognosis. Although most DLBCL patients can achieve good responses in rituximab-based combination therapy, more than one-third of patients still have refractory relapse or disease progression. Due to the phenotypic and genetic heterogeneity of DLBCL, targeting epigenetic modifications, immune checkpoints, tumor immune microenvironment (TIME), and molecular signaling pathways constitute a new pattern of anti-tumor treatment for DLBCL. In order to improve the clinical efficacy of patients, it is crucial to explore the intrinsic characteristics of DLBCL patients and discover new biomarkers.

[0004] Glycosylation is a post-translational modification that can regulate cell function and TIME. Glycosylation can play an important role in the development and treatment of tumors by adding specific glycan structures to corresponding proteins and lipids through glycosyltransferases and glycosidases. Specifically, changes in glycosylation modifications in tumors can affect the transduction of signal pathways, regulate cell-cell interactions, and the sensitivity of tumor cells to chemotherapy and targeted drugs. Sialylation is an important glycosylation terminal modification. Sialic acid is attached to glycoproteins or glycolipids in the form of sugar chains by sialyltransferases. Studies have confirmed that abnormal sialylation modification plays an important role in tumor progression, metastasis, and immune escape.

[0005] ST6GALNAC4 belongs to the aminogalactose α-2,6-sialyltransferase family and catalyzes the transfer of sialic acid from cytidine monophosphate (CMP)-sialic acid to galactose-containing substrates to produce O-glycan branched disialyl structures. ST6GALNAC4 is usually present in the Golgi apparatus and can be processed into soluble proteins by proteolysis. Increasing evidence shows that abnormal expression of ST6GALNAC4 is associated with tumor progression, metastasis, and immune escape. In chronic lymphocytic leukemia (CLL), ST6GALNAC4 can form disialyl-T structures in the glycan epitopes of sialic acid-binding immunoglobulin-like lectin 7 (Siglec-7) ligands, promote the binding of ligands to Siglec-7 on the surface of B cells in leukemia patients, protect B cells from NK cell cytotoxicity, and promote tumor immune escape in vivo. Further studies have shown that MYC regulates the formation of disialyl-T structure by ST6GALNAC4, and the combined high expression of MYC and ST6GALNAC4 can identify high-risk cancer patients. However, the mechanism of action of ST6GALNAC4 in DLBCL is still unclear. Summary of the invention

[0006] In view of the deficiencies of the above-mentioned prior art, the present invention provides the application of aminogalactose α-2,6-sialyltransferase in the diagnosis and treatment of diffuse large B-cell lymphoma. Specifically, the present invention has found through research that ST6GALNAC4-mediated sialylation is an important epigenetic modification in DLBCL, and the sialyltransferase inhibitor 3Fax-Peracetyl Neuc5Ac combined with the BCL-6 inhibitor FX1 has a synergistic effect in DLBCL and can effectively inhibit the growth of tumor cells. Based on the above research results, the present invention is completed.

[0007] In order to achieve the above technical objectives, the present invention adopts the following technical solutions:

[0008] The first aspect of the present invention provides the use of a reagent for detecting the expression level of the gene encoding α-2,6-sialyltransferase ST6GALNAC4 and its expression product in the preparation of a product for screening, diagnosis, detection, monitoring or prognosis evaluation of diffuse large B-cell lymphoma.

[0009] A second aspect of the present invention provides a system for screening, diagnosing, detecting, monitoring or prognostic evaluation of diffuse large B-cell lymphoma, the system comprising:

[0010] An acquisition module, which is configured to include: a detection reagent for determining the expression level of a gene encoding ST6GALNAC4 and its expression product in a test sample of a subject, and;

[0011] An evaluation module is configured to include: evaluating the disease condition of the subject according to the expression levels of the ST6GALNAC4 encoding gene and its expression products determined in the acquisition module.

[0012] The third aspect of the present invention provides the use of a substance for inhibiting the expression of ST6GALNAC4 encoding gene and its expression product or reducing its activity in any one or more of the following:

[0013] (a) preparing a product for inhibiting proliferation of diffuse large B-cell lymphoma cells;

[0014] (b) preparing a product for promoting apoptosis of diffuse large B-cell lymphoma cells;

[0015] (c) preparing a product that blocks the cell cycle and affects the growth of diffuse large B-cell lymphoma cells;

[0016] (d) preparing a medicament for treating diffuse large B-cell lymphoma.

[0017] The fourth aspect of the present invention provides the use of a substance that inhibits the expression of ST6GALNAC4 encoding gene and its expression product or reduces its activity in combination with a BCL-6 inhibitor in the preparation of a diffuse large B-cell lymphoma drug.

[0018] The fifth aspect of the present invention provides a pharmaceutical composition for diffuse large B-cell lymphoma, the active ingredients of which include the above-mentioned substance that inhibits the expression of ST6GALNAC4 encoding gene and its expression product or reduces its activity and a BCL-6 inhibitor.

[0019] A sixth aspect of the present invention provides a method for treating diffuse large B-cell lymphoma, comprising administering to a subject the above-mentioned substance that inhibits the expression of the ST6GALNAC4 encoding gene and its expression product or reduces its activity or the above-mentioned pharmaceutical composition.

[0020] Compared with the existing technical solutions, the above one or more technical solutions have the following beneficial effects:

[0021] The above technical scheme verifies the expression of sialyltransferase ST6GALNAC4 and its clinical significance. Its biological function is evaluated by virus-mediated knockdown of ST6GALNAC4 gene and endogenous overexpression. Experiments such as cell proliferation and flow cytometry have demonstrated the synergistic anti-tumor effect of 3Fax-Peracetyl Neu5Ac combined with FX1 in diffuse large B-cell lymphoma cells, which provides a more favorable means for the diagnosis and prognosis evaluation of diffuse large B-cell lymphoma. It also lays an experimental foundation and provides a new perspective for the development of efficient drugs for the treatment of diffuse large B-cell lymphoma, so it has good practical application value. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.

[0023] Figure 1 In the examples of the present invention, the abnormal expression of DLBCL sialyltransferase is related to the poor prognosis of patients; (A) GEO dataset analysis of the expression difference of sialyltransferase in DLBCL patients and normal control group; (B) ST6GALNAC4 is highly expressed in DLBCL patients; (C) Survival analysis shows that patients with high expression of ST6GALNAC4 have a shorter survival time; (D) The mRNA expression level of ST6GALNAC4 is increased in DLBCL cell lines; (E) The protein expression level of ST6GALNAC4 is significantly increased in DLBCL cell lines.

[0024] Figure 2 In the examples of the present invention, after knocking down STGALNAC4, the proliferation of DLBCL cells was inhibited.

[0025] (AB) qRT-PCR and WB were used to detect viral transfection efficiency; (C) CCK-8 detection showed that knockdown of ST6GALNAC4 inhibited the proliferation of DLBCL cells; (D, G) After knockdown of ST6GALNAC4, the apoptosis of DLBCL cells increased; (E) Knockdown of ST6GALNAC4 induced the increased expression of pro-apoptotic proteins; (F, I) Knockdown of ST6GALNAC4 arrested the cell cycle at the G0 / G1 phase; (H) Knockdown of ST6GALNAC4 induced the decreased expression of cyclin D1 and CDK2.

[0026] Figure 3In the present invention, 3Fax-Peracetyl Nec5A cooperates with FX1 to effectively inhibit the proliferation of DLBCL cells. (A) After treatment with 3Fax-Peracetyl Neu5Ac, the expression level of ST6GALNAC4 protein in DLBCL cell lines was significantly inhibited; (BC) 3Fax-Peracetyl Neu5Ac treatment inhibited the proliferation of DLBCL cells; (DE) FX1 treatment inhibited the proliferation of DLBCL cells; (F) 3Fax-Peracetyl Neu5Ac combined with FX1 significantly reduced the cell viability of DLBCL cell lines. DETAILED DESCRIPTION

[0027] It should be noted that the following detailed descriptions are illustrative and are intended to provide further explanation of the present application. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present application belongs.

[0028] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit the exemplary embodiments according to the present application. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should be understood that when the terms "comprising" and / or "including" are used in this specification, it indicates the presence of features, steps, operations, devices, components and / or combinations thereof. In addition, the molecular biology methods not described in detail in the examples are all conventional methods in the art, and the specific operations can be referred to the molecular biology guide or product manual.

[0029] In a typical embodiment of the present invention, a reagent for detecting the expression level of the gene encoding α-2,6-sialyltransferase ST6GALNAC4 and its expression product is provided for use in preparing a product for screening, diagnosis, detection, monitoring or prognosis evaluation of diffuse large B-cell lymphoma.

[0030] Wherein, the prognosis evaluation at least includes an evaluation of the patient's survival probability. Specifically, the present invention has found through research that ST6GALNAC4 is highly expressed in DLBCL patients; and survival analysis shows that patients with high expression of ST6GALNAC4 have a shorter survival time; at the same time, the mRNA expression levels of ST6GALNAC4 and the protein expression levels of ST6GALNAC4 in DLBCL cell lines are significantly increased. This indicates that it is abnormally highly expressed in diffuse large B-cell lymphoma and is associated with poor prognosis of patients.

[0031] The expression product of the gene encoding α-2,6-sialyltransferase ST6GALNAC4 may be a transcription product or a translation product thereof, such as ST6GALNAC4 mRNA and ST6GALNAC4 protein.

[0032] In another embodiment of the present invention, a system for screening, diagnosing, detecting, monitoring or prognostic evaluation of diffuse large B-cell lymphoma is provided, the system comprising:

[0033] An acquisition module, which is configured to include: a detection reagent for determining the expression level of a gene encoding ST6GALNAC4 and its expression product in a test sample of a subject, and;

[0034] An evaluation module is configured to include: evaluating the disease condition of the subject according to the expression levels of the ST6GALNAC4 encoding gene and its expression products determined in the acquisition module.

[0035] The expression product of the gene encoding α-2,6-sialyltransferase ST6GALNAC4 may be a transcription product or a translation product thereof, such as ST6GALNAC4 mRNA and ST6GALNAC4 protein.

[0036] The subject may be suffering from or suspected of having diffuse large B-cell lymphoma;

[0037] The sample to be tested is a blood sample, such as a peripheral venous blood sample.

[0038] Assessing the subject's disease condition at least includes (auxiliary) diagnosis of whether the subject suffers from diffuse large B-cell lymphoma and assessing the prognosis of the subject suffering from diffuse large B-cell lymphoma, wherein the prognosis at least includes the survival probability of patients with diffuse large B-cell lymphoma.

[0039] In another specific embodiment of the present invention, there is provided the use of a substance for inhibiting the expression of ST6GALNAC4 encoding gene and its expression product or reducing its activity in any one or more of the following:

[0040] (a) preparing a product for inhibiting proliferation of diffuse large B-cell lymphoma cells;

[0041] (b) preparing a product for promoting apoptosis of diffuse large B-cell lymphoma cells;

[0042] (c) preparing a product that blocks the cell cycle and affects the growth of diffuse large B-cell lymphoma cells;

[0043] (d) preparing a medicament for treating diffuse large B-cell lymphoma.

[0044] Among them, substances that inhibit the expression of ST6GALNAC4 encoding gene and its expression products or reduce their activity include but are not limited to RNA interference molecules or antisense oligonucleotides against ST6GALNAC4, small molecule inhibitors (such as 3Fax-PeracetylNeu5Ac, CAS: 117405-58-0), siRNA, shRNA, substances for implementing lentiviral infection or gene knockout, and specific antibodies against ST6GALNAC4 itself or its upstream and downstream molecules, such as anti-ST6GALNAC4 antibodies.

[0045] In (a)-(c), the product can be a drug or a test reagent, and the test reagent can be a common test reagent for non-medical use, so as to construct a tumor model (such as a cell or animal model) to study the mechanism of occurrence and development of tumors such as diffuse large B-cell lymphoma.

[0046] In the above (b), promoting apoptosis of diffuse large B-cell lymphoma cells is specifically manifested in increased expression levels of pro-apoptotic proteins Bax, Cleaved-Caspase3 and Cleaved-PARP.

[0047] In the above (c), blocking the cell cycle affects the growth of diffuse large B-cell lymphoma cells, specifically blocking the diffuse large B-cell lymphoma cell cycle at the G0 / G1 phase, and reducing the expression levels of cell cycle regulatory proteins Cyclin D1 and CDK2.

[0048] In another specific embodiment of the present invention, there is provided use of a substance that inhibits the expression of ST6GALNAC4 encoding gene and its expression product or reduces its activity in combination with a BCL-6 inhibitor in the preparation of a diffuse large B-cell lymphoma drug.

[0049] Specifically, the substance that inhibits the expression of the ST6GALNAC4 coding gene and its expression product or reduces its activity can be 3Fax-Peracetyl Neu5Ac, and the BCL-6 inhibitor can be FX1 (CAS: 1426138-42-2). Studies have shown that the combination of the two can significantly reduce the cell viability of DLBCL cell lines, and therefore has a strong synergistic inhibitory effect on diffuse large B-cell lymphoma.

[0050] The molar ratio of 3Fax-Peracetyl Neu5Ac to FX1 is 1-50:1, further 5-15:1, and further 10:1 (at this time, the concentration range of 3Fax-Peracetyl Neu5Ac is 500-100 μM, and the concentration range of FX1 is 50-100 μM).

[0051] In another specific embodiment of the present invention, a pharmaceutical composition for diffuse large B-cell lymphoma is provided, wherein the active ingredients include the above-mentioned substance that inhibits the expression of the ST6GALNAC4 encoding gene and its expression product or reduces its activity and a BCL-6 inhibitor.

[0052] Specifically, the substance that inhibits the expression of the ST6GALNAC4 coding gene and its expression product or reduces its activity can be 3Fax-Peracetyl Neu5Ac, and the BCL-6 inhibitor can be FX1 (CAS: 1426138-42-2). The molar ratio of 3Fax-Peracetyl Neu5Ac to FX1 is 1-50:1, further 5-15:1, and further 10:1 (at this time, the concentration range of 3Fax-Peracetyl Neu5Ac is 500-100 μM, and the concentration range of FX1 is 50-100 μM). At this time, the two show a significant synergistic effect.

[0053] The pharmaceutical composition may further include at least one inactive pharmaceutical ingredient. The inactive pharmaceutical ingredient may be a carrier, excipient, diluent, etc. commonly used in pharmacy. The inactive pharmaceutical ingredients such as carriers, excipients, diluents, etc. that may be included are well known in the art, and a person of ordinary skill in the art can determine that they meet clinical standards, and are not specifically limited here.

[0054] In another specific embodiment of the present invention, a method for treating diffuse large B-cell lymphoma is provided, comprising administering to a subject the above-mentioned substance that inhibits the expression of the ST6GALNAC4 encoding gene and its expression product or reduces its activity or the above-mentioned pharmaceutical composition.

[0055] The present invention is further described below in conjunction with specific examples, which are only for the purpose of explaining the present invention and are not intended to limit the content thereof. If the specific experimental conditions are not specified in the examples, they are usually carried out according to conventional conditions or the conditions recommended by the sales company; unless otherwise specified in the present invention, they can all be purchased through commercial channels.

[0056] Example

[0057] Study population and data collection

[0058] This study included 100 newly diagnosed DLBCL patients and 30 patients with reactive lymphocyte hyperplasia (RHL) diagnosed in the Provincial Hospital Affiliated to Shandong First Medical University. Survival information was collected by following up the included patients through the hospital case system. In addition, peripheral venous blood was collected from 3 healthy volunteers for sorting CD19+B lymphocytes. Each experiment in this study was approved by the Medical Ethics Committee. Every action taken was in accordance with the requirements of the Declaration of Helsinki. Each volunteer gave informed consent.

[0059] Cell culture

[0060] OCI-LY1, OCI-LY3, OCI-LY8, OCI-LY10 DLBCL cell lines were cultured in IMDM (Gibco, MD, USA) and mixed with 10% FBS (Gibco). Short tandem repeats (STRs) and mycoplasma infection were regularly detected in all cells. FX1 is a BCL-6 inhibitor purchased from selleck (S8591, USA).

[0061] Establishment of stable knockdown cell lines

[0062] GeneChem (Shanghai, China) constructed lentiviral vectors encoding control short hairpin RNA (shRNA), targeting ST6GALNAC4 knockdown, overexpression and empty vectors (wherein the nucleotide sequences of ST6GALNAC4-RNAi#1, ST6GALNAC4-RNAi#2 and ST6GALNAC4-RNAi#3 are shown in SEQ ID NOs. 1-3). Lentivirus transfection was performed according to the manufacturer's instructions, and stably transfected cells were selected by puromycin 72 hours after transfection, and the transfection efficiency was verified.

[0063] Real-time quantitative PCR (qRT-PCR)

[0064] For total RNA extraction, TRIzol reagent (TaKaRa, Shiga, Japan) was used. cDNA library was assembled using reverse transcriptase (AG11706, Accurate Biology, China). qRT-PCR amplification reaction was performed on a LightCycler 480II system (Roche) using SYBR Green Premix Pro Taq HS qPCR Kit (Accurate Biotechnology).

[0065] Protein extraction and western blotting (WB)

[0066] A mixture of RIPA buffer (Beyotime, P0013B) and 1× phosphatase inhibitor (PhosSTOP, Roche, Basel, Switzerland) was used to extract the cell lysate. The protein extracts were electrophoresed on SDS-PAGE and transferred to polyvinylidene difluoride membranes (Millipore, MA, USA) for immunoblotting.

[0067] Cell viability assay

[0068] Cell proliferation was detected by Cell Counting Kit-8 (CCK-8) assay (Dojindo, CK04, MD, USA). DLBCL cells were added to 105 cells / well in a 96-well plate, stained with 10 μl CCK-8 / well at a given time, and cultured for 4 hours. Multiskan GO microplate reader (Thermo Scientific, Rockford, IL, USA) was used to measure the optical density at 450 nm.

[0069] Statistical analysis

[0070] Graphpad Prism (V8.0) statistical software was used for statistical analysis and drawing. The experimental data of each experiment were from at least 3 independent repeated experiments, and the mean ± standard deviation (SD) was used to represent the experimental results. When p < 0.05, it was considered statistically significant.

[0071] Experimental Results

[0072] The expression level of α-2,6-sialyltransferase ST6GALNAC4 is elevated in DLBCL and is associated with poor prognosis of patients

[0073] Sialylation modification is the addition of sialic acid to specific proteins by sialyltransferases. Therefore, we explored the biomarkers in the sialyltransferase family that are most relevant to the prognosis of DLBCL. Bioinformatics analysis of the GEO database dataset revealed that compared with other sialyltransferases, ST6GALNAC4 was differentially expressed in DLBCL ( Figure 1 A). The volcano plot based on differentially expressed genes further confirmed that ST6GALNAC4 was significantly overexpressed in DLBCL patients ( Figure 1 B). Survival analysis found that DLBCL patients with high expression of ST6GALNAC4 had a poor survival status ( Figure 1 C). qRT-PCR and WB further confirmed that the protein expression level of ST6GALNAC4 was also significantly higher than that of CD19+B lymphocytes ( Figure 1D, E). The above results indicate that ST6GALNAC4 has potential prognostic value in DLBCL.

[0074] Knockdown of STGALNAC4 inhibits proliferation of DLBCL cells

[0075] In order to clarify the biological function of ST6GALNAC4 in DLBCL, GCB (OCI-LY1 and OCI-LY8) and non-GCB (OCI-LY10 and U2932) DLBCL subtype cell lines were transfected with lentivirus to construct a cell model with stable knockdown of ST6GALNAC4 (ST6GALNAC4-KD). The viral transfection efficiency was verified by qRT-PCR and WB, and the viral sequence with the highest transfection efficiency was selected for subsequent experiments ( Figure 2 AB). CCK-8 cell proliferation experiments showed that after knocking down ST6GALNAC4, the cell proliferation of both DLBCL subtype cell lines was inhibited to varying degrees. Importantly, the proliferation inhibition of GCB subtype cells was more significant ( Figure 2 C). Based on the relevant research background and our experimental data, we selected OCI-LY1 and OCI-LY8 cell lines for subsequent experiments. The experiment showed that knocking down ST6GALNAC4 promoted apoptosis of DLBCL cells ( Figure 2 D, G), in DLBCL cells with low expression of ST6GALNAC4, the expression levels of pro-apoptotic proteins Bax, Cleaved-Caspase3 and Cleaved-PARP were increased ( Figure 2 E). In addition, knockdown of ST6GALNAC4 arrested the cell cycle at the G0 / G1 phase ( Figure 2 F, I), the expression of cell cycle regulatory proteins Cyclin D1 and CDK2 was decreased ( Figure 2 H). The above results demonstrate that knocking down ST6GALNAC4 affects the growth of DLBCL cells by inhibiting cell proliferation, promoting cell apoptosis and arresting the cell cycle.

[0076] 3Fax-Peracetyl Neu5Ac synergizes with FX1 to effectively inhibit the proliferation of DLBCL cells

[0077] Based on the above research results, we consider that inhibition of sialylation may be a potential therapeutic target for DLBCL. 3Fax-Peracetyl Neu5Ac is a sialyltransferase inhibitor. Immunoblotting experiments showed that 3Fax-PeracetylNeu5Ac can reduce the protein expression level of ST6GALNAC4 in a concentration-dependent manner ( Figure 3 A). Cell proliferation experiments showed that 3Fax-Peracetyl Neu5Ac could reduce the cell proliferation of DLBCL cell lines ( Figure 3 B, C). Considering that the expression of BCL-6 is associated with a lower overall survival rate in DLBCL, we selected the BCL-6 inhibitor FX1. Cell proliferation experiments showed that FX1 can reduce cell proliferation in DLBCL cell lines ( Figure 3 D, E). We further explored whether the combination of 3Fax-Peracetyl Neu5Ac and FX1 has a synergistic anti-tumor effect in DLBCL. The results confirmed that compared with single therapy, 3Fax-Peracetyl Neu5Ac combined with FX1 significantly reduced the cell viability of DLBCL cell lines and had a synergistic effect (Table 1 and Figure 3 F).

[0078] Table 1 Combined index CI values ​​at actual experimental points

[0079]

[0080] The above description is only the preferred embodiment of the present application and is not intended to limit the present application. For those skilled in the art, the present application may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present application shall be included in the protection scope of the present application.

Claims

1. Use of a reagent for detecting the expression level of the gene encoding α-2,6-sialyltransferase ST6GALNAC4 and its expression product in the preparation of a product for screening, diagnosis, detection, monitoring or prognosis evaluation of diffuse large B-cell lymphoma.

2. The use according to claim 1, characterized in that: The expression product of the α-2,6-sialyltransferase ST6GALNAC4 encoding gene is its transcription product or translation product, including ST6GALNAC4 mRNA and ST6GALNAC4 protein.

3. A system for screening, diagnosing, detecting, monitoring or prognostic assessment of diffuse large B-cell lymphoma, characterized in that: The system comprises: An acquisition module, which is configured to include: a detection reagent for determining the expression level of a gene encoding ST6GALNAC4 and its expression product in a test sample of a subject, and; An evaluation module is configured to include: evaluating the disease condition of the subject according to the expression levels of the ST6GALNAC4 encoding gene and its expression products determined in the acquisition module.

4. The system according to claim 3, characterized in that The subject has or is suspected of having diffuse large B-cell lymphoma; The sample to be tested is a blood sample, including a peripheral venous blood sample.

5. The system according to claim 3, characterized in that Assessing the subject's disease condition at least includes (auxiliary) diagnosis of whether the subject suffers from diffuse large B-cell lymphoma and assessing the prognosis of the subject suffering from diffuse large B-cell lymphoma, wherein the prognosis at least includes the survival probability of patients with diffuse large B-cell lymphoma.

6. Use of a substance that inhibits the expression of ST6GALNAC4 encoding gene and its expression product or reduces its activity in any one or more of the following: (a) preparing a product for inhibiting proliferation of diffuse large B-cell lymphoma cells; (b) preparing a product for promoting apoptosis of diffuse large B-cell lymphoma cells; (c) preparing a product that blocks the cell cycle and affects the growth of diffuse large B-cell lymphoma cells; (d) preparing a medicament for treating diffuse large B-cell lymphoma.

7. The use according to claim 6, characterized in that Substances that inhibit the expression of ST6GALNAC4 encoding genes and their expression products or reduce their activity include RNA interference molecules or antisense oligonucleotides, small molecule inhibitors (including 3Fax-Peracetyl Neu5Ac), siRNA, shRNA against ST6GALNAC4, substances for implementing lentiviral infection or gene knockout, and specific antibodies against ST6GALNAC4 itself or its upstream and downstream molecules.

8. The use according to claim 7, characterized in that In (a)-(c), the product is a drug or a test reagent, and the test reagent is a common test reagent for non-medical use; In (b), the promotion of apoptosis of diffuse large B-cell lymphoma cells is specifically manifested in the increased expression levels of pro-apoptotic proteins Bax, Cleaved-Caspase3 and Cleaved-PARP; In the above (c), blocking the cell cycle affects the growth of diffuse large B-cell lymphoma cells, specifically blocking the diffuse large B-cell lymphoma cell cycle at the G0 / G1 phase, and reducing the expression levels of cell cycle regulatory proteins Cyclin D1 and CDK2.

9. Use of substances that inhibit the expression of ST6GALNAC4 encoding gene and its expression products or reduce their activity in combination with BCL-6 inhibitors in the preparation of diffuse large B-cell lymphoma drugs; Furthermore, the substance that inhibits the expression of the ST6GALNAC4 coding gene and its expression product or reduces its activity is 3Fax-Peracetyl Neu5Ac, and the BCL-6 inhibitor is FX1.

10. A pharmaceutical composition for diffuse large B-cell lymphoma, characterized in that: Its active ingredients include substances that inhibit the expression of ST6GALNAC4 encoding gene and its expression products or reduce their activity and BCL-6 inhibitors; Furthermore, the substance that inhibits the expression of the ST6GALNAC4 coding gene and its expression product or reduces its activity is 3Fax-Peracetyl Neu5Ac, and the BCL-6 inhibitor is FX1.